Nizatidine

Research use only, not for human use.

Nizatidine is a histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion.

Nizatidine is a histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion.(In Vivo):Nizatidine (oral gavage; 27 mg/kg; once daily; at 12 weeks of age and were sacrificed at 30 weeks after development of HCC in the setting of nonalcoholic steatohepatitis (NASH)) results in a 35% reduction of tumor nodules relative to controls. Nizatidine results in a 60% reduction in tumor nodules, reduces collagen proportional area and expression of profibrotic markers in DEN-injured rats.Nizatidine (oral gavage; 27 mg/kg; once daily; 4 weeks) decreases the incidence of gastric ulceration, and significantly decreases the mean ulcer score and ulcer index in male albino rats.

——

Nizatidine (oral gavage; 27 mg/kg; once daily; at 12 weeks of age and were sacrificed at 30 weeks after development of HCC in the setting of nonalcoholic steatohepatitis (NASH)) results in a 35% reduction of tumor nodules relative to controls. Nizatidine results in a 60% reduction in tumor nodules, reduces collagen proportional area and expression of profibrotic markers in?DEN-injured rats.Nizatidine (oral gavage; 27 mg/kg; once daily; 4 weeks) decreases the incidence of gastric ulceration, and significantly decreases the mean ulcer score and ulcer index in male albino rats. Animal Model:Male albino ratsDosage:27 mg/kgAdministration:Oral gavage; 27 mg/kg; once daily; 4 weeks Result:Was effective in the management of NSAIDs induced peptic ulcer in rats.

LY139037

Endocrinology/Hormones

AChR

AChE| H2 receptor

Inflammation/Immunology

——

76963-41-2

331.46

C12H21N5O2S2

>98% (HPLC)

Ethanol: 18 mg/mL (54.3 mM); Water: 28 mg/mL (84.47 mM); DMSO: 66 mg/mL (199.11 mM)

CN/C(NCCSCC1=CSC(CN(C)C)=N1)=C\[N+]([O-])=O

(E)-N-(2-(((2-((dimethylamino)methyl)thiazol-4-yl)methyl)thio)ethyl)-N-methyl-2-nitroethene-1,1-diamine

(-20℃)

With Ice Pack

≥ 2 years